Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Currency
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Charles River Laboratories Intl (CRL)
NYSE:CRL
Charles River Labs (CRL) Stock Price & Analysis
442 Followers
CRL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$161.65 - $262.00
Previous Close$204.46
Volume507.75K
Average Volume (3M)532.54K
Market Cap
$10.49B
Enterprise Value$13.28B
Total Cash (Recent Filing)$157.17M
Total Debt (Recent Filing)$2.90B
Price to Earnings (P/E)22.1
Beta1.44
Next Earnings
Feb 14, 2024EPS Estimate
$2.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.23
Shares Outstanding51,296,804
10 Day Avg. Volume399,501
30 Day Avg. Volume532,537
Standard Deviation0.10
R-Squared0.56
Alpha-0.00225
Financial Highlights & Ratios
Price to Book (P/B)-22.37
Price to Sales (P/S)2.64
Price to Cash Flow (P/CF)12.70
P/FCF Ratio15.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.44
Enterprise Value/Gross Profit9.08
Enterprise Value/Ebitda12.97
Forecast
1Y Price Target
$210.00Price Target Upside2.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Charles River Labs News
Pre-EarningsCRL Upcoming Earnings Report: What to Expect?
Ownership Overview
2.66% Insiders
32.14% Mutual Funds
61.41% Other Institutional Investors
3.79% Public Companies and
Individual Investors
CRL FAQ
What was Charles River Laboratories Intl’s price range in the past 12 months?
Charles River Laboratories Intl lowest stock price was $161.65 and its highest was $262.00 in the past 12 months.
What is Charles River Laboratories Intl’s market cap?
Currently, no data Available
When is Charles River Laboratories Intl’s upcoming earnings report date?
Charles River Laboratories Intl’s upcoming earnings report date is Feb 14, 2024 which is in 66 days.
How were Charles River Laboratories Intl’s earnings last quarter?
Charles River Laboratories Intl released its earnings results on Nov 08, 2023. The company reported $2.72 earnings per share for the quarter, beating the consensus estimate of $2.357 by $0.363.
Is Charles River Laboratories Intl overvalued?
According to Wall Street analysts Charles River Laboratories Intl’s price is currently Undervalued.
Does Charles River Laboratories Intl pay dividends?
Charles River Laboratories Intl does not currently pay dividends.
What is Charles River Laboratories Intl’s EPS estimate?
Charles River Laboratories Intl’s EPS estimate is $2.41.
How many shares outstanding does Charles River Laboratories Intl have?
Charles River Laboratories Intl has 51,296,803 shares outstanding.
What happened to Charles River Laboratories Intl’s price movement after its last earnings report?
Charles River Laboratories Intl reported an EPS of $2.72 in its last earnings report, beating expectations of $2.357. Following the earnings report the stock price went down -3.742%.
Which hedge fund is a major shareholder of Charles River Laboratories Intl?
Among the largest hedge funds holding Charles River Laboratories Intl’s share is Ariel Investments LLC. It holds Charles River Laboratories Intl’s shares valued at 209M.
---
Charles River Labs Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$210.00 (2.71% Upside)
$210.00 (2.71% Upside)
Blogger Sentiment
Bullish
CRL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 159.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $700.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Positive
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.67%
12-Months-Change
Fundamentals
Return on Equity
16.01%
Trailing 12-Months
Asset Growth
3.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Charles River Laboratories Intl
Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
---
Top 5 ETFs holding CRL
Global X S&P 500 Covered Call ETF
$766.27K
iShares ESG Screened S&P 500 ETF
$52.96K
Global X S&P 500 Covered Call & Growth ETF
$16.42K
Global X S&P 500 Risk Managed Income ETF
$6.89K
Global X S&P 500 Tail Risk ETF
$811.08
Up to five ETFs with an Outperform Smart Score that hold CRL. The ETFs are listed according to market value of CRL within the ETF
---